SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
Trade name: Ezetimibe / Rosuvastatin Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
Use of the Substance/Mixture: Pharmaceutical

1.3 Details of the supplier of the safety data sheet
Company: MSD
Shotton Lane
NE23 3JU Cramlington NU - Great Britain
Telephone: 44 1 670 59 30 00
Telefax: 908-735-1496
E-mail address of person responsible for the SDS: EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)
Carcinogenicity, Category 1B: H350: May cause cancer.
Reproductive toxicity, Category 1B: H360FD: May damage fertility. May damage the unborn child.
Specific target organ toxicity - single exposure, Category 2: H371: May cause damage to organs.
Specific target organ toxicity - repeated exposure, Category 2: H373: May cause damage to organs through prolonged or repeated exposure.
Long-term (chronic) aquatic hazard, Category 2: H411: Toxic to aquatic life with long lasting effects.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)
Hazard pictograms:

Signal word: Danger
Hazard statements: H350 May cause cancer.
Ezetimibe / Rosuvastatin Formulation

Precautionary statements:

Prevention:
P201 Obtain special instructions before use.
P260 Do not breathe dust.
P273 Avoid release to the environment.
P280 Wear protective gloves/protective clothing/eye protection/face protection.

Response:
P308 + P311 IF exposed or concerned: Call a POISON CENTER/doctor.
P391 Collect spillage.

Hazardous components which must be listed on the label:
Rosuvastatin

2.3 Other hazards
Dust contact with the eyes can lead to mechanical irritation.
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>EC-No.</th>
<th>Index-No.</th>
<th>Registration number</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ezetimibe</td>
<td>163222-33-1</td>
<td></td>
<td></td>
<td></td>
<td>Aquatic Chronic1; H410</td>
<td>&gt;= 2,5 - &lt; 10</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>M-Factor (Chronic aquatic toxicity): 1</td>
<td></td>
</tr>
<tr>
<td>Rosuvastatin</td>
<td>147098-20-2</td>
<td></td>
<td></td>
<td></td>
<td>Carc.1B; H350 Repr.1B; H360FD STOT SE1; H370 STOT RE1; H372 Aquatic Chronic1; H410</td>
<td>&gt;= 2,5 - &lt; 10</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>M-Factor (Chronic aquatic toxicity): 1</td>
<td></td>
</tr>
<tr>
<td>Sodium n-dodecyl sulfate</td>
<td>151-21-3</td>
<td></td>
<td></td>
<td></td>
<td>Acute Tox.4; H302</td>
<td>&gt;= 1 - &lt; 2,5</td>
</tr>
</tbody>
</table>
SECTION 4: First aid measures

4.1 Description of first aid measures

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled: If inhaled, remove to fresh air. Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person.

4.2 Most important symptoms and effects, both acute and delayed

Risks: May cause cancer. May damage fertility. May damage the unborn child. May cause damage to organs. May cause damage to organs through prolonged or repeated exposure.

Dust contact with the eyes can lead to mechanical irritation.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment: Treat symptomatically and supportively.
SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media:
- Water spray
- Alcohol-resistant foam
- Carbon dioxide (CO2)
- Dry chemical

Unsuitable extinguishing media:
None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during firefighting:
Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

Hazardous combustion products:
- Carbon oxides
- Fluorine compounds
- Nitrogen oxides (NOx)
- Sulphur oxides
- Metal oxides

5.3 Advice for firefighters

Special protective equipment for firefighters:
In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

Specific extinguishing methods:
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions:
Use personal protective equipment. Follow safe handling advice and personal protective equipment recommendations.

6.2 Environmental precautions

Environmental precautions:
Discharge into the environment must be avoided. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
6.3 Methods and material for containment and cleaning up

Methods for cleaning up: Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures: Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
Local/Total ventilation: If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling: Do not get on skin or clothing.
Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage: Keep in properly labelled containers. Store locked up. Keep
SAFETY DATA SHEET  
according to Regulation (EC) No. 1907/2006

Ezetimibe / Rosuvastatin Formulation

areas and containers tightly closed. Store in accordance with the particular national regulations.

Advice on common storage: Do not store with the following product types: Strong oxidizing agents, Organic peroxides, Explosives, Gases.

7.3 Specific end use(s)
Specific use(s): No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ezetimibe</td>
<td>163222-33-1</td>
<td>TWA</td>
<td>25 µg/m3 (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>250 µg/100 cm²</td>
<td>Internal</td>
</tr>
<tr>
<td>Rosuvastatin</td>
<td>147098-20-2</td>
<td>TWA</td>
<td>20 µg/m3 (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>200 µg/100 cm²</td>
<td>Internal</td>
</tr>
</tbody>
</table>

 Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

<table>
<thead>
<tr>
<th>Substance name</th>
<th>End Use</th>
<th>Exposure routes</th>
<th>Potential health effects</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium n-dodecyl sulfate</td>
<td>Workers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>285 mg/m3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Skin contact</td>
<td>Long-term systemic effects</td>
<td>4060 mg/kg bw/day</td>
</tr>
<tr>
<td>Consumers</td>
<td>Inhalation</td>
<td></td>
<td>Long-term systemic effects</td>
<td>85 mg/m3</td>
</tr>
<tr>
<td>Consumers</td>
<td>Skin contact</td>
<td></td>
<td>Long-term systemic effects</td>
<td>2440 mg/kg bw/day</td>
</tr>
<tr>
<td>Consumers</td>
<td>Ingestion</td>
<td></td>
<td>Long-term systemic effects</td>
<td>24 mg/kg bw/day</td>
</tr>
</tbody>
</table>

 Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

<table>
<thead>
<tr>
<th>Substance name</th>
<th>Environmental Compartment</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium n-dodecyl sulfate</td>
<td>Fresh water</td>
<td>0.176 mg/l</td>
</tr>
<tr>
<td></td>
<td>Marine water</td>
<td>0.018 mg/l</td>
</tr>
<tr>
<td></td>
<td>Sewage treatment plant</td>
<td>1.35 mg/l</td>
</tr>
<tr>
<td></td>
<td>Fresh water sediment</td>
<td>6.97 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td></td>
<td>Marine sediment</td>
<td>0.697 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td></td>
<td>Soil</td>
<td>1.29 mg/kg dry</td>
</tr>
</tbody>
</table>

6 / 24
8.2 Exposure controls

Engineering measures
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

Personal protective equipment

Eye protection: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection

Material: Chemical-resistant gloves
Remarks: Consider double gloving.

Skin and body protection

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.

Respiratory protection

If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type: Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance: powder
Colour: white to off-white
Odour: No data available
Odour Threshold: No data available
pH: No data available
Melting point/freezing point: No data available
Initial boiling point and boiling range: No data available
Flash point: Not applicable
Evaporation rate: Not applicable
Flammability (solid, gas): May form explosive dust-air mixture during processing, han-
Ezetimibe / Rosuvastatin Formulation

SECTION 9: Physical and Chemical properties

     Upper explosion limit / Upper flammability limit : No data available
     Lower explosion limit / Lower flammability limit : No data available
     Vapour pressure : Not applicable
     Relative vapour density : Not applicable
     Relative density : No data available
     Density : No data available
     Solubility(ies)  
      Water solubility : No data available
      Partition coefficient: n-octanol/water : Not applicable
     Auto-ignition temperature : No data available
     Decomposition temperature : No data available
     Viscosity  
      Viscosity, kinematic : Not applicable
     Explosive properties : Not explosive
     Oxidizing properties : The substance or mixture is not classified as oxidizing.

9.2 Other information

     Flammability (liquids) : No data available
     Molecular weight : No data available
     Particle size : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity
     Not classified as a reactivity hazard.

10.2 Chemical stability
     Stable under normal conditions.

10.3 Possibility of hazardous reactions
     Hazardous reactions : May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.

10.4 Conditions to avoid
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ezetimibe / Rosuvastatin Formulation

Version 1.4
Revision Date: 09/13/2019
SDS Number: 3178946-00005
Date of last issue: 24.04.2019
Date of first issue: 18.09.2018

Conditions to avoid:
- Heat, flames and sparks.
- Avoid dust formation.

10.5 Incompatible materials
Materials to avoid: Oxidizing agents

10.6 Hazardous decomposition products
No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Information on likely routes of exposure:
- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity
Not classified based on available information.

Product:
Acute oral toxicity: Acute toxicity estimate: > 2.000 mg/kg
Method: Calculation method

Components:

Ezetimibe:
Acute oral toxicity: LD50 (Rat): > 5.000 mg/kg
LD50 (Mouse): > 5.000 mg/kg
LD50 (Dog): > 3.000 mg/kg

Acute inhalation toxicity: Remarks: No data available

Acute dermal toxicity: Remarks: No data available

Acute toxicity (other routes of administration):
LD50 (Rat): > 2.000 mg/kg
Application Route: Intraperitoneal
LD50 (Mouse): > 1.000 - < 2.000 mg/kg
Application Route: Intraperitoneal

Rosuvastatin:
Acute oral toxicity: LD50 (Rat): > 2.000 mg/kg
Target Organs: Liver, Stomach, muscle, Kidney

Sodium n-dodecyl sulfate:
Acute oral toxicity: LD50 (Rat): 1.200 mg/kg
Method: OECD Test Guideline 401
Acute dermal toxicity: LD50 (Rat): > 2,000 mg/kg
   Method: OECD Test Guideline 402
   Remarks: Based on data from similar materials

Skin corrosion/irritation
Not classified based on available information.

Components:

Ezetimibe:
   Species: Rabbit
   Result: No skin irritation

Sodium n-dodecyl sulfate:
   Species: Rabbit
   Result: Skin irritation

Serious eye damage/eye irritation
Not classified based on available information.

Components:

Ezetimibe:
   Species: Rabbit
   Result: No eye irritation

Sodium n-dodecyl sulfate:
   Species: Rabbit
   Method: OECD Test Guideline 405
   Result: Irreversible effects on the eye

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Components:

Ezetimibe:
   Test Type: Maximisation Test
   Species: Guinea pig
   Result: negative

Sodium n-dodecyl sulfate:
   Test Type: Maximisation Test
   Exposure routes: Skin contact
   Species: Guinea pig
Ezetimibe / Rosuvastatin Formulation

Result: negative
Remarks: Based on data from similar materials

Germ cell mutagenicity
Not classified based on available information.

Components:

Ezetimibe:
Genotoxicity in vitro:
- Test Type: Bacterial reverse mutation assay (AMES)
  Metabolic activation: with and without metabolic activation
  Result: negative
- Test Type: Chromosomal aberration
  Test system: Human lymphocytes
  Result: negative

Genotoxicity in vivo:
- Test Type: Micronucleus test
  Species: Mouse
  Cell type: Bone marrow
  Application Route: Oral
  Result: negative

Rosuvastatin:
Genotoxicity in vitro:
- Test Type: Bacterial reverse mutation assay (AMES)
  Test system: Escherichia coli
  Result: negative
- Test Type: Chromosomal aberration
  Test system: Chinese hamster lung cells
  Result: negative

Genotoxicity in vivo:
- Test Type: Micronucleus test
  Species: Mouse
  Cell type: Bone marrow
  Application Route: Ingestion
  Result: negative

Sodium n-dodecyl sulfate:
Genotoxicity in vitro:
- Test Type: Bacterial reverse mutation assay (AMES)
  Method: OECD Test Guideline 471
  Result: negative
- Test Type: In vitro mammalian cell gene mutation test
  Result: negative

Genotoxicity in vivo:
- Test Type: Rodent dominant lethal test (germ cell) (in vivo)
  Species: Mouse
  Application Route: Ingestion
  Result: negative
Carcinogenicity
May cause cancer.

Components:

Ezetimibe:
Species: Rat, female
Application Route: oral (feed)
Exposure time: 104 weeks
Result: negative

Species: Rat, male
Application Route: oral (feed)
Exposure time: 104 weeks
Result: negative

Species: Mouse
Application Route: oral (feed)
Exposure time: 104 weeks
Result: negative

Rosuvastatin:
Species: Rat
Application Route: Oral
Exposure time: 104 weeks
LOAEL: 80 mg/kg body weight
Result: positive
Symptoms: Tumour
Target Organs: Uterus (including cervix)

Species: Mouse
Application Route: Oral
Exposure time: 107 weeks
LOAEL: 200 mg/kg body weight
Result: positive
Symptoms: liver adenoma, carcinoma
Target Organs: Liver

Sodium n-dodecyl sulfate:
Species: Rat
Application Route: Ingestion
Exposure time: 2 Years
Method: OECD Test Guideline 453
Result: negative
Remarks: Based on data from similar materials

Reproductive toxicity
May damage fertility. May damage the unborn child.

Components:

Ezetimibe:
### Ezetimibe / Rosuvastatin Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.4</td>
<td>09/13/2019</td>
<td>3178946-00005</td>
<td>24.04.2019</td>
<td>18.09.2018</td>
</tr>
</tbody>
</table>

**Effects on fertility**
- **Test Type**: Fertility/early embryonic development  
- **Species**: Rat, male and female  
- **Fertility**: NOAEL: > 1.000 mg/kg body weight  
- **Result**: No effects on fertility, No fetotoxicity  

**Effects on foetal development**
- **Test Type**: Development  
- **Species**: Rat  
- **Application Route**: Oral  
- **Developmental Toxicity**: NOAEL: > 1.000 mg/kg body weight  
- **Result**: No adverse effects

**Rosuvastatin**

**Effects on fertility**
- **Test Type**: Fertility  
- **Species**: Rat  
- **Application Route**: Oral  
- **Fertility**: NOAEL: 50 mg/kg body weight

**Effects on foetal development**
- **Test Type**: Development  
- **Species**: Rat  
- **Application Route**: Oral  
- **Developmental Toxicity**: LOAEL: 50 mg/kg body weight  
- **Result**: Effects on male and female reproductive organs.

**Reproductive toxicity - Assessment**
- May damage fertility. May damage the unborn child.

**Sodium n-dodecyl sulfate**

**Effects on fertility**
- **Test Type**: Two-generation reproduction toxicity study  
- **Species**: Rat  
- **Application Route**: Ingestion  
- **Method**: OECD Test Guideline 416  
- **Result**: negative  
- **Remarks**: Based on data from similar materials

**Effects on foetal development**
- **Test Type**: Embryo-foetal development  
- **Species**: Rat
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ezetimibe / Rosuvastatin Formulation

Version: 1.4
Revision Date: 09/13/2019
SDS Number: 3178946-00005
Date of last issue: 24.04.2019
Date of first issue: 18.09.2018

Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

**STOT - single exposure**
May cause damage to organs.

**Components:**

**Rosuvastatin:**
- Exposure routes: Oral
- Target Organs: Liver, Kidney, muscle
- Assessment: Causes damage to organs.

**STOT - repeated exposure**
May cause damage to organs through prolonged or repeated exposure.

**Components:**

**Rosuvastatin:**
- Exposure routes: Oral
- Target Organs: Eye
- Assessment: Causes damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity**

**Components:**

**Ezetimibe:**
- Species: Dog
- NOAEL: 1.000 mg/kg
- Application Route: Oral
- Exposure time: 90 d
- Remarks: No significant adverse effects were reported

Species: Rat
- NOAEL: 1.500 mg/kg
- Application Route: Oral
- Exposure time: 90 d
- Remarks: No significant adverse effects were reported

Species: Mouse
- NOAEL: 500 mg/kg
- Application Route: Oral
- Exposure time: 90 d
- Remarks: No significant adverse effects were reported

Species: Dog
- NOAEL: 300 mg/kg
- Application Route: Oral
- Exposure time: 1 yr
- Remarks: No significant adverse effects were reported
## Rosuvastatin:
- **Species**: Dog
- **LOAEL**: 90 mg/kg
- **Application Route**: Oral
- **Exposure time**: 24 Days
- **Target Organs**: Brain
- **Symptoms**: Oedema, Blood disorders, Necrosis
- **Remarks**: Based on data from similar materials

**Species**: Dog
- **LOAEL**: 6 mg/kg
- **Application Route**: Oral
- **Exposure time**: 52 Weeks
- **Target Organs**: Cornea
- **Symptoms**: Corneal opacity
- **Remarks**: Based on data from similar materials

**Species**: Dog
- **LOAEL**: 30 mg/kg
- **Application Route**: Oral
- **Exposure time**: 12 Weeks
- **Target Organs**: Eye
- **Symptoms**: Eye disease
- **Remarks**: Based on data from similar materials

**Species**: Dog
- **LOAEL**: 90 mg/kg
- **Application Route**: Oral
- **Exposure time**: 4 Weeks
- **Target Organs**: eye - retina
- **Symptoms**: Eye disease
- **Remarks**: Based on data from similar materials

## Sodium n-dodecyl sulfate:
- **Species**: Rat
- **NOAEL**: 488 mg/kg
- **Application Route**: Ingestion
- **Exposure time**: 90 Days
- **Remarks**: Based on data from similar materials

**Aspiration toxicity**
Not classified based on available information.

## Components:

**Ezetimibe**: Not applicable
Experience with human exposure

Components:

Ezetimibe:
Ingestion
Symptoms: Headache, Nausea, Vomiting, Diarrhoea, flatulence, muscle pain, upper respiratory tract infection, Back pain, joint pain

Rosuvastatin:
Ingestion
Target Organs: Kidney
Symptoms: kidney toxicity
Remarks: Based on Human Evidence
Target Organs: muscle
Symptoms: musculoskeletal pain
Remarks: Based on Human Evidence
Target Organs: Liver
Symptoms: liver function change
Remarks: Based on Human Evidence

SECTION 12: Ecological information

12.1 Toxicity

Components:

Ezetimibe:
Toxicity to fish
LC50 (Pimephales promelas (fathead minnow)): > 0,125 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates
EC50 (Daphnia magna (Water flea)): > 4 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic plants
EC50 (Pseudokirchneriella subcapitata (green algae)): > 0,317 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility

NOEC (Pseudokirchneriella subcapitata (green algae)): 0,317 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms
EC50: > 4,4 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ezetimibe / Rosuvastatin Formulation

Version 1.4 Revision Date: 09/13/2019 SDS Number: 3178946-00005 Date of last issue: 24.04.2019 Date of first issue: 18.09.2018

NOEC : 4,4 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic toxicity): NOEC: 0,051 mg/l
Exposure time: 33 d
Species: Pimephales promelas (fathead minnow)
Method: OECD Test Guideline 210
NOEC: 4 mg/l
Exposure time: 7 d
Species: Cyprinodon variegatus (sheepshead minnow)
Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity): NOEC: 0,282 mg/l
Exposure time: 21 d
Species: Daphnia magna (Water flea)
Remarks: No toxicity at the limit of solubility

M-Factor (Chronic aquatic toxicity): 1

Rosuvastatin:
Toxicity to fish: LC50 (Pimephales promelas (fathead minnow)): > 1.000 mg/l
Exposure time: 96 hrs
Method: FDA 4.11
LC50 (Lepomis macrochirus (Bluegill sunfish)): > 1.000 mg/l
Exposure time: 96 hrs
Method: FDA 4.11

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 63 mg/l
Exposure time: 48 hrs
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants: EC50 (Microcystis aeruginosa (blue-green algae)): > 640 mg/l
Exposure time: 96 hrs
Method: FDA 4.01
NOEC (Microcystis aeruginosa (blue-green algae)): 330 mg/l
Exposure time: 96 hrs
Method: FDA 4.01
EC50 (Pseudokirchneriella subcapitata (green algae)): > 800 mg/l
Exposure time: 96 hrs
Method: FDA 4.01
NOEC (Pseudokirchneriella subcapitata (green algae)): 350 mg/l
Exposure time: 96 hrs
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ezetimibe / Rosuvastatin Formulation

Version 1.4
Revision Date: 09/13/2019
SDS Number: 3178946-00005
Date of last issue: 24.04.2019
Date of first issue: 18.09.2018

Method: FDA 4.01

Toxicity to microorganisms: EC50: > 100 mg/l
Exposure time: 3 hrs
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC: 100 mg/l
Exposure time: 3 hrs
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Toxicity to fish (Chronic toxicity): NOEC: 1 mg/l
Exposure time: 32 Days
Species: Pimephales promelas (fathead minnow)
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity): NOEC: 0.018 mg/l
Exposure time: 21 Days
Species: Daphnia magna (Water flea)
Method: OECD Test Guideline 211

M-Factor (Chronic aquatic toxicity): 1

Sodium n-dodecyl sulfate:

Toxicity to fish: LC50 (Pimephales promelas (fathead minnow)): 29 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates: EC50 (Ceriodaphnia dubia (water flea)): 5.55 mg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants: ErC50 (Desmodesmus subspicatus (green algae)): > 120 mg/l
Exposure time: 72 h

NOEC (Desmodesmus subspicatus (green algae)): 30 mg/l
Exposure time: 72 h

Toxicity to microorganisms: EC50: 135 mg/l
Exposure time: 3 h

Toxicity to fish (Chronic toxicity): NOEC: >= 1,357 mg/l
Exposure time: 42 d
Species: Pimephales promelas (fathead minnow)

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity): NOEC: 0.88 mg/l
Exposure time: 7 d
Species: Ceriodaphnia dubia (water flea)

12.2 Persistence and degradability

Components:

Ezetimibe:
## 12.3 Bioaccumulative potential

### Components:

**Ezetimibe:**
- **Bioaccumulation**
  - Species: Lepomis macrochirus (Bluegill sunfish)
  - Exposure time: 97 d
  - Bioconcentration factor (BCF): 173
  - Method: OECD Test Guideline 305
- **Partition coefficient: n-octanol/water**
  - log Pow: 4.36

**Rosuvastatin:**
- **Partition coefficient: n-octanol/water**
  - log Pow: 0.3

**Sodium n-dodecyl sulfate:**
- **Partition coefficient: n-octanol/water**
  - log Pow: 0.83

## 12.4 Mobility in soil

### Components:

**Ezetimibe:**
- **Distribution among environmental compartments**
  - log Koc: 4.35
  - Method: OECD Test Guideline 106

**Rosuvastatin:**
- **Distribution among environmental compartments**
  - log Koc: 2.15
  - Method: FDA 3.08
12.5 Results of PBT and vPvB assessment
Not relevant

12.6 Other adverse effects
No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

| Product | Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. |
| Contaminated packaging | Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product. |

SECTION 14: Transport information

14.1 UN number

| ADN | UN 3077 |
| ADR | UN 3077 |
| RID | UN 3077 |
| IMDG | UN 3077 |
| IATA | UN 3077 |

14.2 UN proper shipping name

| ADN | ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ezetimibe, Rosuvastatin) |
| ADR | ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ezetimibe, Rosuvastatin) |
| RID | ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ezetimibe, Rosuvastatin) |
| IMDG | ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ezetimibe, Rosuvastatin) |
| IATA | Environmentally hazardous substance, solid, n.o.s. (Ezetimibe, Rosuvastatin) |

14.3 Transport hazard class(es)

| ADN | 9 |
Ezetimibe / Rosuvastatin Formulation

ADR : 9
RID : 9
IMDG : 9
IATA : 9

14.4 Packing group

| ADR | Packing group : III |
|     | Classification Code : M7 |
|     | Hazard Identification Number : 90 |
|     | Labels : 9 |

| RID | Packing group : III |
|     | Classification Code : M7 |
|     | Hazard Identification Number : 90 |
|     | Labels : 9 |
|     | Tunnel restriction code : (-) |

| IMDG | Packing group : III |
|      | Labels : 9 |
|      | EmS Code : F-A, S-F |

| IATA (Cargo) | Packing instruction (cargo aircraft) : 956 |
|              | Packing instruction (LQ) : Y956 |
|              | Packing group : III |
|              | Labels : Miscellaneous |

| IATA (Passenger) | Packing instruction (passenger aircraft) : 956 |
|                  | Packing instruction (LQ) : Y956 |
|                  | Packing group : III |
|                  | Labels : Miscellaneous |

14.5 Environmental hazards

| ADN | Environmentally hazardous : yes |
|     | ADR | Environmentally hazardous : yes |
|     | RID | Environmentally hazardous : yes |
|     | IMDG | Environmentally hazardous : yes |
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ezetimibe / Rosuvastatin Formulation

Marine pollutant : yes

IATA (Passenger)
Environmentally hazardous : yes

IATA (Cargo)
Environmentally hazardous : yes

14.6 Special precautions for user
The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code
Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture
REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII) : Not applicable
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59) : Not applicable
REACH - List of substances subject to authorisation (Annex XIV) : Not applicable
Regulation (EC) No 1005/2009 on substances that deplete the ozone layer : Not applicable
Regulation (EC) No 850/2004 on persistent organic pollutants : Not applicable
Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals : Not applicable

<table>
<thead>
<tr>
<th>E2</th>
<th>ENVIRONMENTAL HAZARDS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Quantity 1</td>
</tr>
<tr>
<td></td>
<td>200 t</td>
</tr>
</tbody>
</table>

Other regulations:
Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.
Young people under the age of 18 are not allowed to use or be exposed to the product professionally. Young people above the age of 15 are, however, except from this rule if the product is a necessary part of their education.

The components of this product are reported in the following inventories:
AICS : not determined
DSL : not determined
IECSC : not determined
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ezetimibe / Rosuvastatin Formulation

Version 1.4
Revision Date: 09/13/2019
SDS Number: 3178946-00005
Date of last issue: 24.04.2019
Date of first issue: 18.09.2018

15.2 Chemical safety assessment
A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information: Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements

H302 : Harmful if swallowed.
H315 : Causes skin irritation.
H318 : Causes serious eye damage.
H350 : May cause cancer.
H360FD : May damage fertility. May damage the unborn child.
H370 : Causes damage to organs if swallowed.
H372 : Causes damage to organs through prolonged or repeated exposure if swallowed.
H410 : Very toxic to aquatic life with long lasting effects.
H412 : Harmful to aquatic life with long lasting effects.

Full text of other abbreviations

Acute Tox. : Acute toxicity
Aquatic Chronic : Long-term (chronic) aquatic hazard
Carc. : Carcinogenicity
Eye Dam. : Serious eye damage
Repr. : Reproductive toxicity
Skin Irrit. : Skin irritation
STOT RE : Specific target organ toxicity - repeated exposure
STOT SE : Specific target organ toxicity - single exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumu-
Ezetimibe / Rosuvastatin Formulation

Classification of the mixture:

<table>
<thead>
<tr>
<th>Class</th>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carc. 1B</td>
<td>H350</td>
<td>Calculation method</td>
</tr>
<tr>
<td>Repr. 1B</td>
<td>H360FD</td>
<td>Calculation method</td>
</tr>
<tr>
<td>STOT SE 2</td>
<td>H371</td>
<td>Calculation method</td>
</tr>
<tr>
<td>STOT RE 2</td>
<td>H373</td>
<td>Calculation method</td>
</tr>
<tr>
<td>Aquatic Chronic 2</td>
<td>H411</td>
<td>Calculation method</td>
</tr>
</tbody>
</table>

Further information

Sources of key data used to compile the Safety Data Sheet:

Classification procedure:

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN